West Pharmaceutical Services (WST)
Salud / Componentes y sistemas de administración para fármacos inyectables
Specialized leader in stoppers, seals, and drug delivery systems for injectable pharmaceuticals, with genuine regulatory moat (FDA/EMA equivalence requirement to switch suppliers) and structural tailwinds in biologics and elastomers for GLP-1. But at ~$351 (44× normalized earnings) it trades well above its category band (P/E 16-22×), with base case 5-year value ~$319 (-2%/year price appreciation, -2% with dividend): Overvalued — real quality, a price that already incorporates growth from several years ahead.
- Price
- $351.30
- Intrinsic value (5y, base)
- $319
- Total annual return (5y)
- -1.6%
- Status (nominal)
- Overvalued
- Margin of safety
- No margin
The essentials
- Specialized manufacturer of elastomeric components (stoppers, seals) and drug delivery systems for injectable pharmaceuticals, with genuine regulatory moat: switching suppliers requires re-demonstrating equivalence to the FDA/EMA/Chinese authorities with large data packages, which anchors the customer.
- Growth is accelerating: trailing twelve-month revenue +12.4%, FY2026 guidance raised to organic +10.0%-11.0%, driven by biologics and elastomers for GLP-1, with mix shifting toward higher-value components with fatter margins (HVP Components/Delivery Devices, +19-30% in Q2-2026) and the exit of the lower-margin SmartDose business.
- But at 44× normalized earnings it trades well above the reference band for a specialized medical device/component manufacturer (P/E 16-22×) — the base return -2% reflects a price that already incorporates several years of guided acceleration, leaving little margin if growth disappoints or if the shift toward oral GLP-1 formulations reduces demand for injectable containers long-term.
Intrinsic value — two valuation methods
Total return at 5 years: -1.6%/year = -1.9% appreciation + 0.3% dividend. The target price ($319) is ex-dividend; the $5 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $195 · Multiples $260) is below the market price ($351).
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $351 trades ~34.9% above its value discounted to today (~$260); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$162.
Thesis
The business
West is a specialized manufacturer of components and delivery systems for injectable pharmaceuticals, with a genuine regulatory moat (the cost and risk of changing from an approved supplier falls on the pharmaceutical customer) and structural tailwinds: demand for biologics and elastomers for GLP-1 treatments is growing strongly, and mix is shifting toward high-value components of wider margin. Return on capital (19.7%) comfortably exceeds the 10% bar.
The valuation
A specialized manufacturer of regulated medical devices/components is valued on P/E of normalized net income (direct equity), with a reference range of ~16-22× for the category. At ~$351 West trades at 44× — well above that range — while the base case starts with the two anchors of guidance that the company raised on Jul-23-2026 (reported revenues midpoint +9.4%, adjusted diluted EPS midpoint $8.95, implying a normalized net margin of ~18.8%) and from there decelerates smoothly toward a ~20.0% margin at year 5, with multiple compressing from 44× to ~20× terminal. That yields ~$319/share at five years → price CAGR of -2%; with the dividend (0.3%), -2% total.
The margin of safety
No margin of safety: the price already discounts a demanding scenario. The price already incorporates several years of guided acceleration by the company itself, leaving little margin if growth disappoints or if the heavy buyback ($454.3M in the first half of 2026) proves less accretive than modeled by paying at a rich multiple. The verdict is Overvalued: a business of genuine quality—regulatory moat, solid ROIC, structural tailwinds—at a price that already pays for that quality and more.
What to watch
Three focal points. First, whether elastomer demand for GLP-1 follows guided pace or whether the shift to oral formulations starts reducing injectable packaging demand in the coming decade. Second, renewal (or not) of the exclusive license with Daikyo, expiring in 2027, which supports part of proprietary technology. Third, whether multiple compression to its category band — the largest return risk at this price — materializes before earnings grow enough to absorb it.
Educational / informational. Does not constitute investment advice.